ATE133423T1 - Rekonstituierte hdl-teilchen und ihre verwendung - Google Patents

Rekonstituierte hdl-teilchen und ihre verwendung

Info

Publication number
ATE133423T1
ATE133423T1 AT88905138T AT88905138T ATE133423T1 AT E133423 T1 ATE133423 T1 AT E133423T1 AT 88905138 T AT88905138 T AT 88905138T AT 88905138 T AT88905138 T AT 88905138T AT E133423 T1 ATE133423 T1 AT E133423T1
Authority
AT
Austria
Prior art keywords
hdl particles
reconstituted hdl
lipid soluble
particle
reconstituted
Prior art date
Application number
AT88905138T
Other languages
English (en)
Inventor
Daniel M Levine
Sanford R Simon
Bruce R Gordon
Thomas S Parker
Stuart D Saal
Albert L Rubin
Original Assignee
Rogosin Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21977929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE133423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rogosin Inst filed Critical Rogosin Inst
Application granted granted Critical
Publication of ATE133423T1 publication Critical patent/ATE133423T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Disintegrating Or Milling (AREA)
AT88905138T 1987-05-20 1988-05-19 Rekonstituierte hdl-teilchen und ihre verwendung ATE133423T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5248987A 1987-05-20 1987-05-20

Publications (1)

Publication Number Publication Date
ATE133423T1 true ATE133423T1 (de) 1996-02-15

Family

ID=21977929

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905138T ATE133423T1 (de) 1987-05-20 1988-05-19 Rekonstituierte hdl-teilchen und ihre verwendung

Country Status (4)

Country Link
EP (1) EP0319557B1 (de)
AT (1) ATE133423T1 (de)
DE (1) DE3854940T2 (de)
WO (1) WO1988009345A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5932536A (en) * 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
AU2006200646B2 (en) * 1997-09-08 2008-09-18 Johnson & Johnson Pharmaceutical Research And Development Llc A method of modulating cellular activity
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US6828306B2 (en) * 2000-07-31 2004-12-07 Ottawa Heart Institute Research Corporation Charged lipid compositions and methods for their use
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
ES2376875T3 (es) 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
KR20120045243A (ko) * 2010-10-29 2012-05-09 사회복지법인 삼성생명공익재단 재구축 ｈｄｌ을 포함하는 평활근 세포 증식 억제용 조성물
EP3714039B1 (de) 2017-11-22 2025-03-12 HDL Therapeutics, Inc. Verfahren zum primen von fluidkreisläufen eines plasmabearbeitungssystems
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3208253A1 (de) * 1982-03-08 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur spezifischen bestimmung des cholesterins der ldl-fraktion im serum
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4499184A (en) * 1982-06-01 1985-02-12 Eastman Kodak Company Analysis for total cholesterol using lecithin:cholesterol acyl transferase (LCAT)
FR2559669B1 (fr) * 1984-02-20 1986-05-09 Nabavi Seyfeddine Lipoproteine haute densite cholesterol synthetique

Also Published As

Publication number Publication date
EP0319557B1 (de) 1996-01-24
WO1988009345A1 (en) 1988-12-01
DE3854940T2 (de) 1996-07-11
EP0319557A4 (en) 1991-05-08
DE3854940D1 (de) 1996-03-07
EP0319557A1 (de) 1989-06-14

Similar Documents

Publication Publication Date Title
ATE133423T1 (de) Rekonstituierte hdl-teilchen und ihre verwendung
Jubert et al. Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
EP0552256A4 (de)
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
IT9020025A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in polvere
ATE92929T1 (de) Komplexe verbindungen aus bioflavonoiden mit phospholipiden, ihre herstellung und verwendung und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
FI954143L (fi) Kiinteitä lipidihiukkasia, bioaktiivisten aineiden hiukkasia, menetelmiä niiden valmistamiseksi ja niiden käyttö
ATA43791A (de) Inhaliergerät und medikamentenpackung hierfür
ATE99949T1 (de) Natuerliches oberflaechenwirksames lungenpraeparat, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen.
EP0221041A3 (de) Benzimidazolderivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
GB2282140A (en) Purified forms of DNAse
ATA318788A (de) Neue derivate der 17beta-oh 19-nor-steroide, die an stelle 17alpha substituiert sind, ihr herstellungsverfahren, ihre anwendung als medikamente und pharmazeutische erzeugnisse, in denen sie enthalten sind
SG32486G (en) Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
ATE40647T1 (de) Extraktionsverfahren von propolis, danach erhaltenes wasserloesliches getrocknetes pulver aus propolis, propolisenthaltende kosmetische und pharmazeutische praeparate.
NL1008021A1 (nl) Nieuwe formulering voor inhalatie.
ATE87467T1 (de) Pharmazeutische zubereitung.
EE03950B1 (et) Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine
PL283722A1 (en) Method for manufacturing phenylhydrazones
Grau et al. Somatic depression among the elderly: A sociocultural perspective.
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
SE8402702L (sv) Anvendning av ett specifikt tumorassocierat antigen i hapten, nemligen fukosylsialosylgangliotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time